Video: Ethical and regulatory use of biospecimens in the EU
Unique considerations surrounding the bureaucracy and oversight in the use of human biospecimens in the European Union.
List view / Grid view
Unique considerations surrounding the bureaucracy and oversight in the use of human biospecimens in the European Union.
A new report has stated that the majority of medical journals restrict their content for pharmaceutical industry professionals.
The government has issued a letter to the pharmaceutical industry, outlining how to prepare for a no-deal Brexit.
Pharmaceutical company, Sanofi, will eliminate jobs in France and Germany and end new in-house cardiology research programmes.
A study has predicted that the global in vitro toxicology market will rise by 8.2 percent in its forecast period.
13 June 2019 | By Sartorius AG
The new generation of modular premium laboratory balances.
The court held that the defendants adulterated and misbranded a stem cell drug product made from a patient’s adipose tissue.
Using exclusively male animals in experiments biases results, argues Rebecca Shansky.
Arizona company claims their products can treat Lyme disease, diabetes, Parkinson’s disease and more, but have not been approved for any use.
16 May 2019 | By
Researchers say they have affirmed inconsistencies in the use of a common laboratory procedure called immunohistochemical staining.
In this issue: AI-driven automated chemistry as a tool to accelerate drug discovery processes, the shifting landscape of immuno-oncology, and how lipid molecules provide an insight into biological research.
Data integrity and computerised system validations (CSV) have become an area of increased scrutiny for regulatory agencies over the last several years. Understanding how the agencies view data integrity is critical for laboratories to maintain complete compliance.
Many bioanalytical labs work with a crowded and siloed set of systems and processes. From part electronic to part paper-based workflows to standalone point-solutions, the result is a lack of insight into data and slower reporting and results handling.
In this issue: Omics-informed drug target discovery in combating emerging infectious diseases, measuring intracellular ATP levels to access compound-mediated cellular toxicity, and turning organoids into physiologically relevant high-content assays for drug discovery.